Stockreport

Cognition Therapeutics Presents Evidence of Zervimesine's Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026 [Yahoo! Finance]

Cognition Therapeutics, Inc.  (CGTX) 
PDF clinical-stage company developing drugs that treat neurodegenerative disorders, presented an analysis from the Phase 2 COG1201 SHIMMER study ( NCT05225415 ) of zervimesi [Read more]